TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04450368

Intervention type: DEVICE
Intervention: Sylvee
Description: The investigators have developed a small sensor that has the same characteristics as a combined hearing aid used for Tinnitus. It has a noise generator intended to transmit white noise (2 - 20 KHz) and a microphone similar to those used in hearing aids to provide sound amplification. Our sensor is substantially equivalent to legally FDA approved marketed devices that can be used for several hours per day. Although it will introduce new indications for use (lung resonance capture), it has the same technological characteristics and will not introduce new hazards or safety risks. Several sound-based devices are already in use for clearing mucus from the lungs by generating and delivering low frequency sound that vibrates the airways and lung secretions, causing them to thin and become expelled. The devices are placed on the patient's chest for up to 3-4 hours in COPD, cystic fibrosis (CF) and other lung diseases.

Intervention type: DEVICE
Intervention: Sylvee
Description: The investigators have developed a small sensor that has the same characteristics as a combined hearing aid used for Tinnitus. It has a noise generator intended to transmit white noise (2 - 20 KHz) and a microphone similar to those used in hearing aids to provide sound amplification. Our sensor is substantially equivalent to legally FDA approved marketed devices that can be used for several hours per day. Although it will introduce new indications for use (lung resonance capture), it has the same technological characteristics and will not introduce new hazards or safety risks. Several sound-based devices are already in use for clearing mucus from the lungs by generating and delivering low frequency sound that vibrates the airways and lung secretions, causing them to thin and become expelled. The devices are placed on the patient's chest for up to 3-4 hours in COPD, cystic fibrosis (CF) and other lung diseases.
Study: NCT05601817

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vita
Description: Vita is developed by this study team based on Attention Restoration Theory. The Vita intervention involves viewing 360 degree nature pictures on a virtual reality headset.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Com
Description: Com intervention uses BrainHQ from PositScience that was developed based on the brain neuroplasticity. The com intervention involves doing game-like training on a iPad.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vita+Com
Description: Vita+Com intervention is a combination of both Vita and Com interventions. Participants will be asked to complete Vita first and then Com intervention.
Study: NCT05056844

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04316546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-7075 (miransertib)
Description: MK-7075 (miransertib) is a small molecule developed by ArQule Inc., a wholly owned subsidiary of Merck Sharp \&amp; Dohme (Merck), that effectively inhibits AKT. Proteus syndrome is caused by mosaic activating mutations in AKT1. This is a Phase 2 trial investigating the efficacy of miransertib as a treatment for adult and pediatric patients with Proteus syndrome.
Study: NCT06073080

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein Nutrition During Recovery
Description: Dietary Protein Nutrition Distribution

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Protein Nutrition During Recovery
Description: Dietary Protein Nutrition Distribution
Study: NCT06145971

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: brief Cognitive Behavioural Therapy for Insomnia (bCBTi)
Description: Two sessions of Cognitive Behavioural Therapy for Insomnia, encompassing a cognitive therapy technique and a behavioural technique as a minimum.
Study: NCT05798026

Intervention type: DRUG
Group type: OTHER
Intervention: EU103
Description: EU103 will be administered via intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EU103
Description: EU103 will be administered via intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EU103
Description: EU103 will be administered via intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EU103
Description: EU103 will be administered via intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EU103
Description: EU103 will be administered via intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EU103
Description: EU103 will be administered via intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EU103
Description: EU103 will be administered via intravenous infusion.
Study: NCT05134857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide
Description: The ZON will be supplied in 100 mg capsules and deposited directly into the TAD device by research staff every 2 weeks. All participants will be told to take 100 mg/day for the first three weeks (Week 1-2 single-blind, placebo-only, induction; end of Week 2, active treatment begins) and increasing by 100 mg/day every other week (Week 4: 200 mg/day; Week 6: 300 mg/day; Week 8: 400 mg/day) up to the target dose of 500 mg/day by Week 10. The participants will be maintained on this dose through Week 14 of active treatment and then tapered off ZON (2 weeks). This dosing schedule is consistent with best practices for ZON. All TAD devices will only dispense the prescribed medication between 4pm and 11pm each night. Participants will be instructed to take the medication at or near bedtime.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The PLO will be supplied at the same schedule and in the same manner (TAD device) as the ZON.
Study: NCT06273293

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Fractional Flow Reserve
Description: Agreement measurements between the different post-ICP functional values (cFFR+NTG and FFR) will be performed at the end of the intervention on the treated vessels. The study protocol consists of 4 sequential steps (separated by at least 30 sec):~1. Determination of FFR with contrast and NTG: cFFR +NTG will be calculated with the lowest ratio after the infusion of 0.2 mg bolus of intracoronary NTG and pushed with contrast.~2. Determination of distal pressure between basal aortic pressure: The Pd/Pa will be obtained after about 30-60 seconds of the NTG bolus in step 1.~3. Determination of the diastolic dPR index: the average value (2-3 determinations).~4. Determination of fractional flow reserve with adenosine: The FFR will be obtained after continuous peripheral venous infusion with adenosine or with intracoronary boluses according to the protocol of each center.
Study: NCT04838613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]CTT1057
Description: Single intravenous dose of approximately 370 Mega-Becquerel (MBq) and subsequent PET/CT scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-PSMA-11
Description: Single intravenous dose of approximately 150 MBq and subsequent PET/CT scan
Study: NCT06431490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2102 for injection
Description: TQB2102 for injection is a HER2 dual-antibody-drug Conjugate (ADC)
Study: NCT04762849

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic one anastomosis gastric bypass
Description: Laparoscopic one anastomosis gastric bypass include the creation of gastric pouch; a jejunal loop measure about 200 cm from the ligament of Treitz and anastomosed to the gastric pouch. For the creation of a gastric pouch and gastroenterostomy use a linear stapler.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic one anastomosis gastric bypass
Description: Laparoscopic one anastomosis gastric bypass include the creation of gastric pouch; a jejunal loop measure about 200 cm from the ligament of Treitz and anastomosed to the gastric pouch. For the creation of a gastric pouch and gastroenterostomy use a linear stapler.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A shape-memory ring for adjustable gastric banding
Description: A shape-memory ring (SMR) use for adjustable gastric banding. SMR is placed around the gastric pouch above the gastro-entero-anastomosis.
Study: NCT04163510

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral: Parent/Child Reading Program
Description: A 9-week parent/child reading program will help parents to identify strategies to establish literacy routines with their children, and to engage with them in enjoyable literacy activities that promote skill building while reducing negative feelings associated with reading. Three large-group sessions will be held in a central location, to build community and rapport among researchers and participants. Six individual sessions will take place in the participants' homes, to customize reading strategies and routines to each family's home setting and personal interests. Intervention sessions will be held once per week for 60-90 minute sessions.
Study: NCT06292585

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MMA embolization plus medical therapy
Description: Patients assigned to the intervention group will receive endovascular embolization treatment within 2 hours after enrollment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical therapy alone
Description: Patients will receive the best conservative treatment recommended by the guidelines, and conservative treatment will be the same in both groups. Conservative treatment includes medication and general treatment. Drug therapy can be divided into hemostatic treatment, antihypertensive treatment, and symptomatic treatment. Specific local clinical diagnosis and treatment standards shall prevail or refer to corresponding clinical guidelines.
Study: NCT05868512

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Dry needling
Description: Dry Needling Along With Routine Physical Therapy for Chronic Neck Pain
Study: NCT05844475

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Free Gingival Graft Approach (FGG)
Description: Conventional Free Gingival Graft Approach involving palatal soft tissue harvesting

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Buccal Strip Graft with a collagen matrix (bSG + CM)
Description: A small strip of keratinized gingiva is harvested from the buccal gingiva of a site showing abundant keratinized gingiva, and combined with a xenogeneic collagen matrix
Study: NCT05368987

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS)
Description: Research subjects will undergo non-invasive TMS, with a frequency of 20Hz and intensity of 120% of their resting motor threshold (rMT) at varying time points and locations.
Study: NCT05868512

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound
Description: Therapeutic ultrasound Along With Routine Physical Therapy for Chronic Neck Pain
Study: NCT05052047

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brisk Walking Group
Description: Brisk Walk: 20 min/day (The researchers found, for most people, brisk walking could be defined as moving at a pace of 2.7 miles per hour or 100 steps per minute for adults under about age 60 or guidelines define brisk walking as occurring when individuals move at a pace that increases their heart rate to about 70% of their heart rate maximum) Patient will also perform breathing exercises as given to Control group, Positioning (lean forward when needed) Percussion coughing when needed

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Breathing Exercise Group
Description: Breathing exercises: 20 min/day~Breathing Ex includes:~• Pursed lip breathing: Sit with your back straight, inhale through your nose for 2 seconds. Purse your lips like you rae blowing on hot food and then breath out slowly, take twice as long to exhale as you took to breath in 4-5 times a day~• Diaphragmatic breathing: Lie on your back on a flat surface, knees bent and head supported. Use pillow under knees to support your legs . breathe in slowly through your nose tighten your stomach, letting them fall inward as you exhale through your pursed lips. Practice these exercises 5-10 minutes about 3-4 times a day.~Positioning (lean forward when needed) Percussion coughing when needed
Study: NCT05368987

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fear Conditioning and Extinction Paradigm
Description: Participants will undergo a 3-day experimental paradigm. On day 1, participants will undergo a resting-state and structural scans in the fMRI scanner. The data from this scan will be used to determine the specific location of the TMS target for each participant. And participants will be aversively conditioned to two cues in the fMRI scanner. Task based and resting-state scans will occur on this day.~On day 2, subjects will undergo extinction training outside of the scanner where one of the conditioned cues will be paired with TMS in a temporally and anatomically specific manner. A resting-state scan will occur before and after inside the scanner.~On day 3, conditioned cues will be presented during the extinction recall phase of the study. This phase will be conducted in the fMRI scanner. Task-based and resting-state scans will occur on this day.
Study: NCT05710315

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReliZORB™
Description: Relizorb cartridges will be used with routine enteral feedings for 5 days for randomized participants

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo cartridges will be used with routine enteral feedings for 5 days for randomized participants
Study: NCT06031623

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: REBOA
Description: Resuscitative endovascular balloon occlusion of the aorta (REBOA)is a device composed of a catheter attached to an inflatable balloon. It is inserted through the common femoral artery and guided to the thoracic aorta.
Study: NCT06474754

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: High-sensitivity troponin, serum
Description: A serum derived measure of myocardial injury. Threshold value of 14ng/L.
Study: NCT06308341

Intervention type: OTHER
Group type: OTHER
Intervention: Virtual Reality technique + Motor Imagery technique + Routine Physical Therapy
Description: Routine physical therapy for 30 minutes is explained as: warm up for 10 mins, stretching of lower limb and upper limb for 10 min, task specific training, gait training and balance training exercises for 15min, strengthening exercises for 10 min

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality + Routine Physical Therapy
Description: Routine physical therapy protocol will be given for 30 minutes along with cycling and walking for 10-15 minutes.~VR techniques for 10-15 minutes The first eight weeks focus on simple activities to enhance balance and motor function, such as tennis, boxing, bowling, kicking, soccer, table tilt, penguin slide, tilt city, single-leg extension, and torso twist. Exercise difficulty is adjusted based on performance, gradually progressing from easier to more challenging activities.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor Imagery +Routine Physical Therapy
Description: Routine physical therapy protocol will be given for 30 minutes along with Cycling and walking for 10-15 minutes MI techniques for 10-15 minutes The motor imagery program me will be performed in three steps; STEP I: The patients will watch the videos recorded by the examiner. STEP II: The patients will be asked to close their eyes, focus, and imagine how they are doing the task they had previously observed ten times.~Step III: The patient will be asked to attempt the activity with his affected limbs according to the verbal command of the examiner Routine physical therapy for 30 minutes is explained as: warm up for 10 mins, stretching of lower limb and upper limb for 10 min, task specific training, gait training and balance training exercises for 15min, strengthening exercises for 10 min.
Study: NCT05725005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASN51
Description: ASN51 formulation for oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASN51
Description: ASN51 formulation for oral capsule
Study: NCT05820568

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICBT-IU
Description: Internet delivered Cognitive Behavior Therapy for Generalized Anxiety Disorder based on the Intolerance of uncertainty model of worry
Study: NCT03692754

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 20mg
Description: Atorvastatin will be given in 20 mg po qn for 1 month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 10mg
Description: Atorvastatin will be given in 10 mg po qn for 1 month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone will be given in 40mg po qd for 4 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone will be given in 40mg po qd for 4 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be given in 40mg po qd for 4 days
Study: NCT05127434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection
Study: NCT06474754

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Submaximal Cardiopulmonary Exercise Testing
Description: FDA-approved device uses breath by breath sampling during calibration and exercise challenge. Analysis is performed using a differential pressure pneumotach method for volume calibration and measurement, an infrared sensor for CO2 and a paramagnetic sensor for O2 measurements. Automated calibration using a calibration gas mixture (15.6% O2/5% CO2) is performed at regular intervals. The Shape II calculations used to differentiate causes of exertional dyspnea are Artificial Intelligence (AI) based algorithms and measurements have been previously validated to conventional cardiopulmonary exercise testing methods. Brief smCPET is comprised of a 2-minute calibration phase, 3 minutes of graded exercise using a stair-step and a 1 minute recovery phase for a total of 6 minutes. An instant report is then generated.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Duke Activity Status Index
Description: A validated measure of preoperative functional capacity which will be utilized to cross-validate smCPET peak VO2. Low DASI score has been found to estimate peak oxygen uptake (VO2), predict MINS, myocardial infarction, and inducible myocardial ischemia on myocardial perfusion scintigraphy.
Study: NCT05127434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mRNA-1345
Description: Sterile liquid for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mRNA-1345
Description: Sterile liquid for injection
Study: NCT04225611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: The investigators have developed a topically-applied corticosteroid-delivery system that has the potential to treat recurrent cystoid macular edema with fewer risks to patient, and more dose control. The system is comprised of a drug-polymer film that is completely encapsulated within the periphery of a hydrogel that is commonly used to make contact lenses.
Study: NCT05593250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1905
Description: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1905
Description: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1905
Description: subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subcutaneous ,placebo
Study: NCT06518577

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flucelvax (ccIIV4)
Description: Participants will receive Flucelvax (ccIIV4)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flublok (RIV) or Fluzone (IIV)
Description: Participants will receive Flublok (RIV) or Fluzone (IIV)
Study: NCT05677113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QBECO
Description: QBECO is a site specific immunomodulator (SSI) designed to promote innate immune responses in the gastrointestinal tract and related organs, including the liver. QBECO will be administered according to the following regimen: 0.1mL self-administered subcutaneous injections every 2 days for 11-120 days preoperatively, and 41 days postoperatively.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be prepared in the same way as the IP. Placebo will be administered according to the following regimen: 0.1mL self-administered subcutaneous injections every 2 days for 11-120 days preoperatively, and 41 days postoperatively.
Study: NCT06258330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AM003
Description: Bispecific Personalized Aptamer for intratumoral administration
Study: NCT05135897

Intervention type: DEVICE
Intervention: Electroconvulsive therapy
Description: Treatment with Electroconvulsive therapy

Intervention type: DEVICE
Intervention: rTMS
Description: repetitive Transcranial Magnetic Stimulation
Study: NCT06258330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AM003
Description: Bispecific Personalized Aptamer for intratumoral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AM003
Description: Bispecific Personalized Aptamer for intratumoral administration
Study: NCT05642442

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsule(s) administered every day (QD) orally. Titration may proceed at a rate of 1 matching placebo capsule per day every 7 days as required for optimal efficacy and tolerability up to a maximum number of 3 matching placebo capsules per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvecaltamide
Description: Suvecaltamide capsule administered every day (QD) orally. Titration may proceed at a rate of 10 mg suvecaltamide per day every 7 days as required for optimal efficacy and tolerability up to a maximum dose of 30 mg suvecaltamide per day.
Study: NCT05612035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5475
Description: MK-5475 380 µg administered as dry powder inhalation once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MK-5475
Description: MK-5475 380 µg administered as dry powder inhalation once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered as dry powder inhalation once daily.
Study: NCT05384106

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: (R)-1,3-butanediol
Description: Avela™ (R)-1,3-butanediol is intended to induce ketosis in the general adult population. Avela™ (R)-1,3-butanediol is GRAS for use in beverages, bars, and gels